Ovarian Cancer Test Results, Diagnosis, and Treatment

An ovarian cancer test is not usually one single test. Diagnosis commonly combines a medical evaluation, pelvic imaging and blood tests, while examination of tissue obtained during surgery is needed to confirm ovarian cancer and identify its type.

Ovarian cancer testing: the answer in brief

An ovarian cancer test may involve a symptom review, pelvic examination, imaging and blood tests. These investigations can identify a suspicious ovarian mass or signs that cancer may be present, but ovarian cancer is generally confirmed only when a pathologist examines tumor tissue under a microscope.

There is currently no reliable routine screening test for ovarian cancer in average-risk people who do not have symptoms. Testing is instead guided by symptoms, examination findings, family history, genetic risk and results of earlier tests. Prompt assessment of persistent symptoms can help clinicians determine whether further investigation is needed.

Ovarian cancer includes several different tumor types and may begin in the ovaries, fallopian tubes or peritoneum, the lining of the abdomen. For related information, see ovarian cancer.

Symptoms and situations that may prompt an ovarian cancer test

Early ovarian cancer may cause no symptoms or symptoms that are easily mistaken for common digestive or urinary conditions. The symptoms most often discussed include persistent abdominal bloating or increased abdominal size, pelvic or abdominal pain, reduced appetite or feeling full sooner than usual, and needing to urinate more often or urgently.

Other possible symptoms include changes in bowel habits, fatigue, unintentional weight change, back pain, pain during sex or abnormal vaginal bleeding. These symptoms are common and usually have causes other than cancer. They are more concerning when they are new, occur frequently, worsen over time, or continue for several weeks.

A clinician may also recommend assessment after finding an adnexal mass during a pelvic examination or an imaging study performed for another reason. People with a strong family history of ovarian, breast, pancreatic, prostate or colorectal cancer may benefit from genetic counseling and individualized risk assessment.

How ovarian cancer is investigated and diagnosed

The assessment usually starts with a medical history and physical examination. A pelvic examination may detect enlargement, tenderness, fluid or a mass, although it cannot reliably detect every ovarian tumor. The clinician will consider menstrual status, pregnancy possibility, other health conditions and family history when interpreting findings.

Transvaginal ultrasound is often the first imaging test for a suspected ovarian or pelvic mass. It can show whether a mass appears fluid-filled, solid or mixed, and whether it has features that need specialist review. CT, MRI or PET imaging may be used to clarify the extent of disease, assess other organs and help plan treatment; imaging alone cannot definitively prove cancer.

Blood tests may include CA-125, a protein that can be elevated in some ovarian cancers. However, CA-125 can also rise with noncancerous conditions such as endometriosis, uterine fibroids, pelvic infection, menstruation, liver disease or pregnancy. Some ovarian cancers do not raise CA-125, especially at earlier stages, so the result must be interpreted alongside imaging and clinical findings.

Additional blood markers may be considered depending on age and the appearance of a mass, particularly when a non-epithelial ovarian tumor is possible. Genetic testing may be recommended for a person diagnosed with epithelial ovarian cancer, since inherited changes such as BRCA1 or BRCA2 can affect treatment decisions and inform relatives about potential risk.

What is the gold standard for diagnosing ovarian cancer?

The gold standard for diagnosing ovarian cancer is histopathologic examination of tumor tissue by a pathologist. In many cases, tissue is obtained during an operation designed to remove the tumor and determine how far it has spread. The pathology report identifies the cancer type, grade and other features that influence treatment planning.

A needle biopsy may be used when surgery is not the safest first step or when imaging suggests disease that cannot be fully removed initially. This can establish the diagnosis before systemic treatment is started. The choice between biopsy and surgery is made by the treating team after considering the person’s health, imaging results and likely treatment pathway.

For suspected ovarian cancer, referral to a gynecologic oncologist is important when available. These specialists are trained in surgery and systemic treatment planning for cancers of the ovaries, fallopian tubes and peritoneum. Accurate staging may include examination and sampling of tissues in the abdomen and pelvis during surgery.

What are the treatment options for ovarian cancer?

Treatment is individualized according to the cancer type, stage, grade, molecular features, previous treatment, symptoms and the person’s overall health and goals. Care is usually planned by a multidisciplinary team that may include a gynecologic oncologist, medical oncologist, radiologist, pathologist, specialist nurses and supportive-care professionals.

Surgery is a central treatment for many patients. Its goals may include removing visible cancer, confirming the stage and relieving symptoms caused by a tumor or fluid buildup. The extent of surgery differs from person to person. In selected early-stage situations, fertility-sparing surgery may be discussed, but this requires careful evaluation of the cancer type and stage.

Chemotherapy, commonly using platinum-based medicines, is frequently given after surgery or sometimes before surgery when reducing tumor burden first is expected to make surgery safer or more effective. The timing and medicines used depend on pathology and treatment history. Information about chemotherapy may help patients understand how systemic cancer medicines are administered and monitored.

Some patients may be offered maintenance treatment after an initial response, including targeted therapies such as PARP inhibitors or anti-angiogenic therapy. Eligibility depends on factors including BRCA-related or other tumor testing, stage, response to platinum chemotherapy and potential side effects. Radiation therapy has a more limited role but may occasionally be considered for specific symptoms or localized areas of disease.

Supportive care is part of treatment at every stage. It can address pain, nausea, fatigue, nutritional needs, menopausal symptoms, emotional wellbeing and practical concerns. Palliative care focuses on quality of life and can be provided alongside active cancer treatment; it is not limited to end-of-life care.

Outlook, recurrence, and long-term survival

Ovarian cancer outlook is influenced by the stage at diagnosis, cancer subtype and grade, whether surgery can remove visible disease, response to treatment, genetic and molecular findings, and general health. Population survival data can describe broad trends, but they cannot predict an individual person’s outcome.

Follow-up after treatment commonly includes visits to review symptoms, examination when appropriate and selected tests or imaging based on the clinical situation. CA-125 may be followed for some people whose level was elevated at diagnosis, but a rising result alone does not always determine when treatment should begin. Decisions should take symptoms, scans, treatment options and personal priorities into account.

Recurrence can occur, particularly with more advanced disease, but further treatment may still control cancer for meaningful periods. Options may include additional surgery in selected cases, chemotherapy, targeted medicines, clinical trials and supportive therapies. Open discussion with the cancer team can help patients understand the purpose and likely benefits and burdens of each option.

Who is a survivor of stage 4 ovarian cancer?

A survivor of stage 4 ovarian cancer is a person who has been diagnosed with stage 4 disease and is living after that diagnosis, whether they are receiving treatment, have no evidence of disease, are living with stable cancer, or have recurrent cancer. Many people and organizations use the word “survivor” from the time of diagnosis onward, while others may prefer terms such as “person living with cancer.”

Stage 4 ovarian cancer means the cancer has spread beyond the abdomen, for example to fluid around the lungs or to distant organs. It is a serious diagnosis, but it does not define one person’s experience or predict exactly how they will respond to care. Treatment can often reduce cancer, ease symptoms and extend disease control, and ongoing advances continue to expand available options.

Emotional support, rehabilitation, symptom management and communication with loved ones can be as important as medical treatment. Oncology teams can connect patients with counseling, support groups, nutrition guidance and other resources that fit their circumstances.

Can you live 20 years after ovarian cancer?

Yes, some people live 20 years or longer after an ovarian Prostate Cancer Diagnosis: Tests and Next Steps" class="ahp-ilk">cancer diagnosis, particularly when cancer is diagnosed at an earlier stage or has favorable biological features and responds well to treatment. Long-term survival is possible, but no clinician can accurately promise a particular timeframe for an individual.

Even after advanced-stage ovarian cancer, outcomes vary considerably. Some people have long periods without detectable disease, while others need treatment at intervals to manage recurrence. Prognosis discussions are most useful when they are based on the individual pathology report, stage, imaging, treatment response and general health rather than statistics alone.

Regular follow-up and attention to new symptoms are important after treatment. Survivorship care may also address bone health, heart health, sexual wellbeing, menopause-related symptoms, emotional recovery and the practical effects of returning to daily life.

When to seek medical care

Medical assessment is appropriate for persistent bloating, pelvic or abdominal pain, early fullness, appetite changes, or urinary urgency or frequency that is new and happens often. A prompt appointment is also sensible for unexplained abdominal swelling, a newly felt pelvic mass, persistent changes in bowel habits, unintentional weight loss or abnormal vaginal bleeding.

Urgent care is needed for severe or sudden abdominal or pelvic pain, fainting, fever with significant pain, heavy bleeding, repeated vomiting, difficulty breathing or a rapidly enlarging abdomen. These symptoms may occur with many conditions, including problems unrelated to cancer, but they should not be ignored.

People with a known inherited cancer-risk gene or a significant family history should discuss a personalized prevention and surveillance plan with a qualified clinician or genetic counselor. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat ovarian cancer for international patients, with care plans based on individual clinical findings.

Frequently asked questions